Safety and efficacy of cerebral embolic protection in transcatheter aortic valve implantation: an updated meta-analysis.
AsiaIntervention
; 10(1): 51-59, 2024 Feb.
Article
in En
| MEDLINE
| ID: mdl-38425806
ABSTRACT
Background:
The use of cerebral embolic protection devices during transcatheter aortic valve implantation (TAVI) reveals conflicting data.Aims:
This updated meta-analysis aims to evaluate the efficacy and safety of the SENTINEL Cerebral Protection System.Methods:
A literature search for relevant studies up to September 2022 was performed. Study outcomes were divided based on time period - overall (up to 30 days) and short (≤7 days). The outcomes studied include stroke (disabling, non-disabling), mortality, neuroimaging findings, transient ischaemic attack, acute kidney injury and major vascular and bleeding complications.Results:
A total of 15 studies involving 294,134 patients were included. Regarding overall outcomes, significant reductions were noted for mortality (odds ratio [OR] 0.60, 95% confidence interval [CI] 0.41-0.88; p=0.008), all stroke (OR 0.64, 95% CI 0.46-0.88; p=0.006) and disabling stroke (OR 0.42, 95% CI 0.23-0.74; p=0.003) using the SENTINEL device. No significant differences were noted for other outcomes. There was significant heterogeneity across the studies for mortality (p=0.013) and all stroke (p=0.003). Including only randomised data (n=4), there was only significant reduction in the incidence of disabling stroke (OR 0.39, 95% CI 0.17-0.89; p=0.026) in the SENTINEL group. In studies reporting ≤7-day outcomes (n=8), use of the SENTINEL device demonstrated significantly lower rates of all stroke (p<0.001), disabling stroke (p<0.001) and major bleeding complications (p=0.02). No differences in neuroimaging outcomes were noted.Conclusions:
In this updated meta-analysis, use of the SENTINEL Cerebral Protection System was associated with lower rates of mortality, all stroke and disabling stroke, although significant heterogeneity was noted for mortality and all stroke. Including exclusively randomised data, there was only significant reduction in the incidence of disabling stroke. No significant adverse outcomes with device use were noted.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
AsiaIntervention
Year:
2024
Type:
Article
Affiliation country:
Singapore